Hetero Drugs Ltd. has announced the launch of a biosimilar for Roche’s Avastin® (bevacizumab) in India. Hetero is marketing the drug under the brand name “CizumabTM” as a treatment for metastatic colorectal cancer.
Hetero’s launch is the second release of an Avastin® biosimilar in India– earlier this month, Reliance Life Sciences launched its own bevacizumab product under the brand name “Bevacirel.”
The post Avastin Biosimilar Launches in India appeared first on Big Molecule Watch.